Topics

GSK launches phase 3 programme for gepotidacin in uUTI and GC

06:19 EDT 29 Oct 2019 | Pharmaceutical Business Review

The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – EAGLE-1 and EAGLE-2.

The post GSK launches phase 3 programme for gepotidacin in uUTI and GC appeared first on Pharmaceutical Business review.

Original Article: GSK launches phase 3 programme for gepotidacin in uUTI and GC

NEXT ARTICLE

More From BioPortfolio on "GSK launches phase 3 programme for gepotidacin in uUTI and GC"

Quick Search